Galera to Host Virtual Key Opinion Leader Event on Radiotherapy-Induced Severe Oral Mucositis (SOM) in Patients with Head and Neck Cancer
September 14 2021 - 07:00AM
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage
biopharmaceutical company focused on developing and commercializing
a pipeline of novel, proprietary therapeutics that have the
potential to transform radiotherapy in cancer, today announced that
the Company will host a virtual Key Opinion Leader event on
radiotherapy-induced severe oral mucositis (SOM) in patients with
head and neck cancer on Thursday, September 23 at 11:00 a.m. ET.
Dr. Carryn Anderson, Clinical Associate
Professor of Radiation Oncology at the University of Iowa, will
provide a review of the current clinical treatment paradigm for
patients with locally advanced head and neck cancer, including the
use of intensity-modulated radiation therapy.
Dr. Anderson’s presentation will be followed by
a video from a head and neck cancer survivor on his experience with
SOM and a presentation from Galera’s President and CEO, Mel
Sorensen, M.D., with an overview of the SOM market in patients with
head and neck cancer.
The live audio webcast of the event will be
accessible from the News & Events section of the Investors page
of Galera’s website at investors.galeratx.com. Individuals can
participate in an interactive Q&A session by submitting
questions via the webcast platform.
An archived version of the webcast will be
available for 30 days following the event.
About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage
biopharmaceutical company focused on developing and commercializing
a pipeline of novel, proprietary therapeutic candidates that have
the potential to transform radiotherapy in cancer. Galera’s lead
product candidate is avasopasem manganese (avasopasem, or GC4419),
a selective small molecule dismutase mimetic in late-stage
development to reduce the incidence and severity of
radiotherapy-induced severe oral mucositis (SOM) in patients with
head and neck cancer. Avasopasem is also in development for
radiotherapy-induced esophagitis in patients with lung cancer.
Avasopasem has been granted FDA Fast Track and Breakthrough Therapy
designations for the reduction of SOM induced by radiotherapy, with
or without systemic therapy. Galera’s second dismutase mimetic
product candidate, GC4711, is in clinical-stage development to
augment the anti-cancer efficacy of stereotactic body radiation
therapy in patients with non-small cell lung cancer and locally
advanced pancreatic cancer. Galera is headquartered in Malvern, PA.
For more information, please visit www.galeratx.com.
Investor Contacts:Christopher DegnanGalera
Therapeutics, Inc.610-725-1500cdegnan@galeratx.com
William WindhamSolebury
Trout646-378-2946wwindham@soleburytrout.com
Media Contact:Zara LockshinSolebury
Trout646-378-2960zlockshin@soleburytrout.com
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Mar 2023 to Mar 2024